BioCentury
ARTICLE | Clinical News

Dificid fidaxomicin regulatory update

November 4, 2013 8:00 AM UTC

The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) published new guidelines recommending fidaxomicin for Clostridium difficile infection (CDI) in all patients suitable for oral antibiotic treatment. Specifically, fidaxomicin is recommended as first-line therapy in CDI patients with first recurrence or risk for recurrent disease and in patients with multiple recurrences of CDI. The guidelines also recommend the antibiotic in patients with severe disease and non-severe CDI. The drug is approved to treat C. difficile-associated diarrhea (CDAD) in the U.S. and EU, where it is known as Dificlir. ...